Insights
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
OHE, in collaboration with Pfizer, hosted an educational symposium entitled “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA methodologies Appropriately Value and Enable Access?”.
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
A Center for Global Development (CGD) paper authored by OHE’s Adrian Towse and CGD’s Rachel Silverman Bonnifield shows a very high expected return on investment (ROI)…
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
How can we identify efficiency variations across general practices and opportunities to improve their productivity if the measurement of output does not reflect the value produced?
Reforming Primary Health Care in Middle-Income Countries: The Good, the Bad, and the Ugly
18 July 2022
A recent series of papers examines the effects of multiple primary health care interventions (introduction of health facility accreditation, introduction of user fees, and discontinuation of performance-based financing schemes) under Egypt’s Health Sector Reform Program between 2000 and 2014.
The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis
30 June 2022
OHE and Vifor Pharma present a poster at the last European Conference on Rare Diseases (ECRD) on the Mechanism of Coordinated Access to orphan medicinal products…
The State of Play for Cost-effectiveness Thresholds
28 June 2022
In a new paper led by OHE, an international team of co-authors considers the evidence for supply-side cost-effectiveness thresholds, providing a set of recommendations for policymakers.…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
Since the Office of Health Economics (OHE) published a critique of CBO’s new simulation model of new drug development late last year, the U.S. public sector…
ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?
6 June 2022
As part of OHE’s presence at ISPOR 2022 in Washington DC, we hosted an issue panel tackling the hot topic of health technology assessment (HTA) of…
Sleepio: Lessons from the Frontier of Digital Therapeutics
31 May 2022
The National Institute for Health and Care Excellence (NICE) recently issued its first guidance for a digital therapeutic. NICE recommends the use of Sleepio for treating…